These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28238634)

  • 1. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.
    Garinis AC; Cross CP; Srikanth P; Carroll K; Feeney MP; Keefe DH; Hunter LL; Putterman DB; Cohen DM; Gold JA; Steyger PS
    J Cyst Fibros; 2017 May; 16(3):401-409. PubMed ID: 28238634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
    Garinis A; Gleser M; Johns A; Larsen E; Vachhani J
    J Cyst Fibros; 2021 Mar; 20(2):278-283. PubMed ID: 32713806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
    Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
    Madaule J; Valenzuela F; Mittaine M; Gallois Y; Baladi B; Murris M; Calmels MN; Concordet D; Gandia P
    J Cyst Fibros; 2023 Sep; 22(5):944-948. PubMed ID: 37088635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.
    Al-Malky G; Suri R; Dawson SJ; Sirimanna T; Kemp D
    Int J Audiol; 2011 Feb; 50(2):112-22. PubMed ID: 21265638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
    Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
    J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
    Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
    J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides.
    Handelsman JA; Nasr SZ; Pitts C; King WM
    Pediatr Pulmonol; 2017 Sep; 52(9):1157-1162. PubMed ID: 28737283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss.
    de Hoog M; van Zanten BA; Hop WC; Overbosch E; Weisglas-Kuperus N; van den Anker JN
    J Pediatr; 2003 Jan; 142(1):41-6. PubMed ID: 12520253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
    Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
    J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients.
    Gleser MA; Zettner EM
    Int J Audiol; 2018 Dec; 57(12):917-924. PubMed ID: 30382794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.
    Braccini G; Lori I; Neri AS; Festini F; Pela I; Ciuti R; Boni V; Zavataro L; Braggion C; De Martino M; Taccetti G
    J Chemother; 2009 Feb; 21(1):101-4. PubMed ID: 19297282
    [No Abstract]   [Full Text] [Related]  

  • 15. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
    LeCleir LK; Pettit RS
    Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
    Patatanian L
    Pediatr Infect Dis J; 2006 Mar; 25(3):276-8. PubMed ID: 16511399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis.
    Saad A; Young MR; Studtmann AE; Autry EB; Schadler A; Beckman EJ; Gardner BM; Wurth MA; Kuhn RJ
    Pediatr Pulmonol; 2020 Dec; 55(12):3384-3390. PubMed ID: 32910553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.
    Scheenstra RJ; Heijerman HG; Zuur CL; Touw DJ; Rijntjes E
    Acta Otolaryngol; 2010 Feb; 130(2):253-8. PubMed ID: 19479457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between hearing loss and peritonitis frequency and administration of ototoxic intraperitoneal antibiotics in patients with CAPD.
    Tokgoz B; Somdas MA; Ucar C; Kocyigit I; Unal A; Sipahioglu MH; Oymak O; Utas C
    Ren Fail; 2010 Jan; 32(2):179-84. PubMed ID: 20199179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?
    Solmaz F; Gündoğdu E; Akduman D; Haksever M; Dikici O; Ünal F
    Toxicol Rep; 2016; 3():401-404. PubMed ID: 28959562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.